Table 1.
Landmark of clinical trials for the HIV vaccines 1.
| Phase | Trial ID | Strategy | Candidate | Volunteers | Outcome |
|---|---|---|---|---|---|
| III | VAX 003 | Protein | AIDSVAX B/E | 2500 | No protection |
| III | VAX 004 | Protein | AIDSVAX B/B | 5400 | No protection |
| IIb | HVTN 502/Merck 023 (STEP Study) | Viral Vector—Adeno | MRKAd5 HIV-1 gag/pol/nef | 3000 | Terminated because of no protection |
| IIb | HVTN 503 (Phambili) | Viral Vector—Adeno | MRKAd5 HIV-1 gag/pol/nef | 3000 | Terminated because of no protection |
| III | RV 144 | Viral Vector—Pox/Protein | ALVAC-HIV-1(vCP1521)/AIDSVAX B/E | 16403 | Partial protection |
| III | HVTN702 | Viral Vector—Pox/Protein | ALVAC-HIV/AIDSVAX B/E | 5400 | Terminated because of no protection |
| IIb | Imbokodo (HPX2008/HVTN705) | Viral Vector—Adeno/Protein | Ad 26-moasic/gp140 | 2637 | The data will be released in 2021 |
| III | Mosaico (HPX3002/HVTN706) | Viral Vector—Adeno/Protein | Ad 26-moasic/gp140 | 3800 | The data will be released in 2023 |
1 Summarized and referenced from the IAVI trials database (http://www.iavireport.org/trials-db/Pages/default.aspx) as of June 2020.